NCT04771572 - Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL. | Biotech Hunter

Enrollment

100

Participants

Timeline

Start Date

August 23, 2021

Primary Completion Date

October 1, 2025

Study Completion Date

October 1, 2025

Conditions

Non Hodgkin LymphomaRichter TransformationMultiple MyelomaT-cell-prolymphocytic LeukemiaAcute Myeloid LeukemiaAcute Lymphocytic LeukemiaMyeodysplastic SyndromeMyelodysplastic/Myeloproliferative NeoplasmMyelofibrosisChronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaChronic Myelomonocytic Leukemia-2Myelodysplastic Neoplasm in Blast Phase

Interventions

DRUG

LP-118

novel, oral, selective treatment for hematological malignancies tested through ascending dose levels

Trial Locations (8)

27514

RECRUITING

University of North Carolina, Chapel Hill

43210

RECRUITING

The Ohio State University, Columbus

45229

RECRUITING

Cincinnati Children's Hospital Medical Center, Cincinnati

RECRUITING

University of Cincinnati, Cincinnati

60637

RECRUITING

University of Chicago, Chicago

77030

RECRUITING

MD Anderson Cancer Center, Houston

84112

RECRUITING

University of Utah, Salt Lake City

02215

RECRUITING

Dana Farber Cancer Institute, Boston